Jason Lettmann
Signal active
Chief Executive Officer
Bio
Jason Lettmann is the CEO of ALX Oncology. He previously worked at Carrick Therapeutics as a Board Member. Jason Lettmann attended the University of Iowa.
Location
Dublin, Dublin, Ireland, Europe
Social
Primary Organization
ALX Oncology
Founded
2015
Employees
11-50
Industry
Biotechnology, Life Science, Health Care, Biopharma, Therapeutics, Oncology
Jobs history
3
ALX Oncology
Chief Executive Officer
2023 - Current
Cerevance
Board Member
Invalid date - Current
Atsena Therapeutics
Board Member
2020 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Jason Lettmann is the Chief Executive Officer at ALX Oncology, based in Europe. With a background in Biotechnology, Jason Lettmann has a rich history of leadership and innovation. Jason Lettmann studied BA Pre-medicine/ Psychology @ University of Iowa. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
N/A
Number of investment
1
Number of exits
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
7
| Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
|---|---|---|---|---|
| Oct 11, 2016 | Relievant Medsystems | Series D - Relievant Medsystems | Morgenthaler Ventures | 36.0M |
| Oct 29, 2020 | Relievant Medsystems | Series F - Relievant Medsystems | Morgenthaler Ventures | 70.0M |
| Dec 16, 2020 | Atsena Therapeutics | Series A - Atsena Therapeutics | Lightstone Ventures | 55.0M |
| Feb 13, 2023 | Cerevance | Series B - Cerevance | Lightstone Ventures | 51.0M |
Morgenthaler VenturesExits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.